Large scale lentiviral vector production

慢病毒载体（LV）在其将其遗传有效载荷插入靶细胞基因组的能力方面是显著的。这会影响目标中的永久性遗传变化，并将其传播给其后代。虽然有几种遗传修饰的方法，但很少有能够永久修饰靶细胞的方法。在所有用于基因递送的载体中，LV在无与伦比的效率、安全性、无毒性和修饰非分裂靶细胞的能力方面是独特的。因此，它们被认为是新兴细胞治疗以及基因治疗行业有效发展所需的关键试剂。然而，尽管LV代表了一种很好理解的和稳健的技术，但是没有用于非常大规模的LV生产的制造方法。这是目前开发的许多细胞和基因治疗产品的临床试验和商业开发的公认瓶颈。我们建议解决这一未满足的需求

Lentiviral vectors (LV) are remarkable in their ability to insert their genetic payload into a target cell's genome. This affects a permanent genetic change in the target which is propagated through to its progeny. While there are several means of genetic modification, few are capable of permanent modification of target cells. Amongst all vectors for gene delivery, LV are unique in unparalleled efficiency, safety, lack of toxicity and ability to modify non-dividing target cells. They have therefore come to be recognised as a key reagent required for the efficient development of the burgeoning cell therapy, as well as gene therapy industries. However, although LV represent a well understood and robust technology, there is no manufacturing methodology for very large-scale LV production. This is now an acknowledged bottle-neck both for clinical trials and for commercial exploitation of many cell and gene therapy products in current development. We propose to address this unmet need